Navigation Links
Wayne State discovers potential treatment for better heart health in hemodialysis patients
Date:1/15/2014

DETROIT Researchers at Wayne State University have discovered a potential way to improve the lipid profiles in patients undergoing hemodialysis that may prevent cardiovascular disease common in these patients. Patients undergoing hemodialysis for kidney failure are at a greater risk for atherosclerosis, a common disease in which plaque builds up inside the arteries. Atherosclerosis can lead to serious problems including heart attack, stroke or even death.

The team of researchers discovered that a unique combination of vitamin E isomers known as tocotrienols improved the patients' lipid profiles. The study, "Vitamin E tocotrienol supplementation improves lipid profiles in chronic hemodialysis patients," was published in a recent issue of the journal, Vascular Health Risk Management, and showed that patients in the randomized double-blind, placebo-controlled parallel trial who were given the vitamin E supplement had notable improvement in their lipid profiles compared to those given the placebo.

"After 12 and 16 weeks of intervention, the hemodialysis patients taking the Vitamin E supplements showed significant improvements in their blood lipid profiles," said Pramod Khosla, Ph.D., associate professor of nutrition & food science in Wayne State University's College of Liberal Arts and Sciences. "Specifically, their triglycerides were reduced and their HDL cholesterol levels increased, as compared to the placebo group."

"This study could potentially have positive clinical implications in the future for hemodialysis patients that need to improve their triglyceride and HDL levels, but first these findings need to be verified in a much larger group of subjects. Additionally, we need to tease out the interactive effects of the tocotrienols with various medications that are routinely prescribed to these patients," added Khosla.

"Accelerated cardiovascular disease is a major problem in the end-stage renal disease population, and these findings may lead to new approaches to understanding its pathophysiology and to treatment," commented James Sondheimer, M.D., associate professor of internal medicine in Wayne State's School of Medicine. "A multicenter trial to confirm these findings and determine clinical significance is clearly called for." Sondheimer was not involved in the study.


'/>"/>

Contact: Julie O'Connor
julie.oconnor@wayne.edu
313-577-8845
Wayne State University - Office of the Vice President for Research
Source:Eurekalert

Related biology news :

1. Wayne State University researchers program targets safer river fishing, anglers health
2. Wayne State researchers working to improve genetic analysis, disorder detection
3. Wayne State receives $2.8 million grant from US Administration for Children and Families
4. New book on physics principles by Wayne State professor explains life as we know it
5. High-strength material advancements at Wayne State University may lead to new, life-saving steel
6. Cancer risk for African-American women with benign breast disease factors Wayne State finds
7. Wayne State University researchers techniques enable more, faster testing of biological liquids
8. Wayne State study shows airborne dust in urban areas impacts lead levels in children
9. Wayne State vision restoration technology receives Notice of Allowance for US patent app
10. Wayne State University startup, Advaita, to participate in new Michigan I-Corps program
11. Wayne State welcomes undergraduates from around the US for physics research experience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers ... The result of a collaboration among several companies with expertise in toolholding, cutting ...
Breaking Biology Technology: